Questran OTC switch for cholesterol lowering set for advisory committee review.
This article was originally published in The Tan Sheet
Executive Summary
BRISTOL-MYERS SQUIBB's QUESTRAN OTC SWITCH ADVISORY COMMITTEE REVIEW by FDA's Nonprescription Drugs and Endocrinologic & Metabolic Drugs Advisory Committees is set for Sept. 27. The committees will review data from Bristol-Myers Squibb's Rx-to-OTC switch NDAs for the cholestyramine products Questran and Questran Light (NDAs 16-640 and 19-669).